Cipla's profit after tax jumped 61.8% to Rs 500 crore stock hits record high

Shares of Cipla have risen 5.13% in two trading sessions from Rs 380.45 on 5 November 2012, after the company after market hours on Monday, 5 November 2012, reported strong Q2 results. The stock had jumped 4.18% to settle at Rs 396.35 on Tuesday, 6 November 2012.



The stock had also witnessed pre-result rally. The stock had rallied 7.3% in four trading sessions to settle at Rs 380.45 on 5 November 2012, from a recent low of Rs 354.55 on 30 October 2012.



Cipla's profit after tax jumped 61.8% to Rs 500 crore on 23.6% growth in gross revenue to Rs 2220 crore in Q2 September 2012 over Q2 September 2011.



The company's operating profit jumped 57.7% to Rs 677 crore in Q2 September 2012 over Q2 September 2011. Operating profit margin edged up to 30.5% of income from operations in Q2 September 2012, from 23.9% in Q2 September 2011.



Cipla said its domestic revenue rose 13.5% to Rs 962 crore in Q2 September 2012 over Q2 September 2011. The growth in domestic revenue was largely on account of growth in anti-asthma, anti-biotics and cardiovascular therapy segments, Cipla said in a statement.



Cipla's exports of formulations jumped 38.2% to Rs 1039 crore in Q2 September 2012 over Q2 September 2011. Exports of active pharmaceutical ingredients (API) rose 9% to Rs 174 crore in Q2 September 2012 over Q2 September 2011. Cipla said the growth in exports was primarily due to growth in anti-depressants, anti-ulcerant and anti-asthma segments.



Cipla manufactures pharmaceutical products which include anti-asthmatics, anti-cancer, anti-inflammatory, anti-depressant and other therapeutic products including animal health care products. With over 34 manufacturing units across the country, Cipla manufactures over 2,000 products in 65 therapies.